Welcome to Solvotrin Therapeutics
Solvotrin Therapeutics creates patent protected new chemical entities (NCEs) and demonstrates early preclinical proof-of-concept ensuring that later development is de-risked. The Company has a special interest in rare (orphan) diseases.
Solvotrin Therapeutics has mapped a development and regulatory pathway for lead drug ST0702 where it will be launched in a rare cholesterol disease and will provide improved effectiveness and tolerability over current treatments.
Other opportunities with ST0702 and other drugs from the patent protected platform include cancer prevention and a rare disease of the kidney.
Solvotrin Therapeutics has attracted a very experienced international team with diverse, complementary disciplines in drug development and business management. This includes highly respected international key opinion leaders, experts in niacin drugs, rare diseases and dyslipidaemia.
Headquartered in Cork, Ireland, Solvotrin Therapeutics also has offices and laboratories in Dublin.